Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

COPD Health Center

Font Size

FDA Approves New Inhaler for COPD

Tudorza Pressair Approved for Long-term Management of COPD
WebMD Health News
Reviewed by Louise Chang, MD

July 24, 2012 -- The FDA has approved a new inhaled drug for the treatment of the lung disease COPD (chronic obstructive pulmonary disease).

The drug, called Tudorza Pressair (aclidinium bromide), is a dry powder inhaler. It improves airflow by relaxing the muscles around the large airways of the lungs. Patients use it twice a day.

Tudorza Pressair is approved for the long-term maintenance of COPD only. It is not a "rescue medication" -- a drug used for sudden breathing problems.

COPD is the umbrella term for chronic lung diseases that include emphysema and chronic bronchitis. The symptoms include:

  • chest tightness
  • chronic cough
  • shortness of breath
  • excessive phlegm

Treatment typically involves the use of bronchodilators to open the airways and make breathing easier, and steroids to help reduce airway swelling and mucus production.

Cigarette smoking is the leading cause of COPD.

Tudorza Pressair Approved

The FDA based its approval of Tudorza Pressair on the results of three studies. The studies included more than 1,270 people with COPD.

All the people in the studies had a history of smoking at least one pack of cigarettes a day for 10 years. Those who used Tudorza Pressair showed improvement in lung function measures.

There are some serious side effects associated with Tudorza Pressair. They include:

Common side effects include:

  • headache
  • inflammation of the nasal passage (nasopharyngitis)
  • cough

Tudorza Pressair is distributed by St. Louis-based Forest Pharmaceuticals.

Today on WebMD

man talking to his doctor
Check your COPD risk.
woman using inhaler
What is the top cause of this condition?
chest x-ray
7 early warning signs.
Senior couple stretching
10 exercises for people With COPD.
Bronchitis Overview
Senior woman blowing dandelion
Living With Copd
human lung graphic
Energy Boosting Foods
red heart and ekg
Living With Copd
Senior couple stretching